Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed
California Assembly Approves Psychedelics Legalization Bill
California is reaching the final stages of psychedelic legalization, as the California State Assembly has passed a bill permitting the possession of certain psychedelics.
The legislation would legalize the possession and cultivation of psilocybin, psilocin, dimethyltryptamine (DMT) and mescaline (excluding peyote). The bill allows for the following possession amounts (but excludes synthetic psychedelics such as LSD and MDMA).
Awakn Life Sciences Submits Clinical Trial Application for Phase 3 Trial
Anthony Tennyson, Awakn CEO: “We are pleased to be working with our partners in the NIHR, MRC, and the University of Exter on this program as we together progress AWKN-P001 closer to potentially treating the first participant in the phase III trial. We are also pleased to have secured ILAP designation for AWKN-P001 with which we will look to initiate discussions in the near-term with the MHRA and NICE on our target development plan and market access in parallel to the executing the phase III.”
PharmaTher Submits New Drug Application to the FDA
Will PharmaTher be the next company to get a psychedelic medicine to market? This is the firm’s game plan as it submits a New Drug Application to the FDA.
PharmaTher has submitted a priority original Abbreviated New Drug Application (“ANDA”) for its KETARX (racemic ketamine) to the Food and Drug Administration for expedited review.
The company’s KETARX ketamine program seems to have FDA support, receiving 5 different Orphan Drug designations by the FDA.
Microdose Partners with Concordia for 2023 Annual Summit in New York City
Microdose is pleased to partner with Concordia for the 2023 Concordia Annual Summit, taking place September 18-20 in New York City.
The 13th Annual Summit will convene the top movers and shakers of today’s world to spark dialogue, promote collaboration, and collectively pave the path toward a more equitable, sustainable future.
“We’re pleased to officially partner with Concordia, presenting the first-ever psychedelic-focused content on their stage. This will be an incredible opportunity to explore the emerging psychedelic ecosystem in front of high-level thought leaders and policymakers from Government, Corporate and Nonprofit Organizations,” said Patrick Moher, President of Microdose Psychedelic Insights.
New Study Shows Candy-Flipping Can Reduce Bad Trips
A new study published in Nature shows that MDMA can reduce difficult experiences with other psychedelics.
“Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences” was published by researchers from Imperial College London and New York University’s Langone Center for Psychedelic Medicine.
The survey followed almost 700 people who’d used LSD or psilocybin, with 27 using MDMA in conjunction with the classic psychedelics. The results suggest that small doses of MDMA can potentially minimize the effects of a bad trip.
